XoGlo (placental mesenchymal stem cell-based exosomes) / Kimera - LARVOL DELTA

Evaluation of the Safety and Efficacy of XoGlo Pro, a Placental Mesenchymal Stem Cell-derived Extracellular Vesicles in Treating COVID-19 Symptoms (clinicaltrials.gov) - P1/2 | N=64 | Not yet recruiting | Sponsor: Kimera Labs Inc.

New P1/2 trial • Infectious Disease • Novel Coronavirus Disease

Kimera Labs Files First FDA Investigational New Drug (IND) Application Using XoGlo for Treatment of ARDS Secondary to COVID-19 (PRNewswire) - "Kimera® Labs Inc...announces the filing of an extended FDA Investigational New Drug (IND) application to study the treatment of COVID-19 related inflammatory disease using Kimera's first-in-class XoGlo® isolated placental mesenchymal stem cell-based exosomes....The Company is proposing a 160 patient clinical trial in a non-hospital ambulatory setting."

IND • Infectious Disease • Novel Coronavirus Disease